Login to Your Account

Financings Roundup

Tesaro Files for $86M IPO to Advance CINV Drug Rolapitant

By Marie Powers
Staff Writer

Tuesday, March 27, 2012
Tesaro Inc. continued its stellar trajectory, filing an S-1 registration statement with the SEC seeking to raise up to $86.3 million in an initial public offering (IPO) to advance rolapitant, its selective neurokinin-1 (NK1) receptor antagonist with an extended plasma half-life.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription